We are live on ! Find out more
KALV

KalVista Pharmaceuticals
KALV

Delisted

KALV was delisted on the 10th of June, 2026.

Back to rankings

128 hedge funds and large institutions have $557M invested in KalVista Pharmaceuticals in 2024 Q1 according to their latest regulatory filings, with 46 funds opening new positions, 33 increasing their positions, 35 reducing their positions, and 11 closing their positions.

New
Increased
Maintained
Reduced
Closed

318% more first-time investments, than exits

New positions opened: 46 | Existing positions closed: 11

38% more funds holding

Funds holding: 93 → 128 (+35)

22% more capital invested

Capital invested by funds: $459M → $557M (+$98.6M)

3.05% more ownership

Funds ownership: 108.32% → 111.37% (+3.1%)

0% more funds holding in top 10

Funds holding in top 10: 4 → 4 (0)

6% less repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 35

86% less call options, than puts

Call options by funds: $1.01M | Put options by funds: $7.04M

Holders
128
Holders Change
+35
Holders Change %
+37.63%
% of All Funds
1.84%
Holding in Top 10
4
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.06%
New
46
Increased
33
Reduced
35
Closed
11
Calls
$1.01M
Puts
$7.04M
Net Calls
-$6.02M
Net Calls Change
-$16.1M

Top Buyers

Rank Fund Capital Flow
1
VA
VR Adviser
New York
+$28.8M
2
Adage Capital Partners
Adage Capital Partners
Massachusetts
+$24.9M
3
SCM
Suvretta Capital Management
New York
+$20.1M
4
Capital World Investors
Capital World Investors
California
+$19.5M
5
FTM
First Turn Management
California
+$15.7M

Top Sellers

Rank Fund Capital Flow
1
TCM
TCG Crossover Management
California
-$29.8M
2
JFG
Jefferies Financial Group
New York
-$13.9M
3
VC
Vivo Capital
California
-$10.5M
4
Citadel Advisors
Citadel Advisors
Florida
-$9.29M
5
DCM
Driehaus Capital Management
Illinois
-$6.49M
Name Holding Trade Value Shares
Change 		Change in
Stake
GI
126
GAMMA Investing
California
$190 – – –
AWM
127
Avior Wealth Management
Nebraska
$59 +$67 +5 New
FFO
128
Fortitude Family Office
Arizona
$36 – – –
FGAM
129
Financial Gravity Asset Management
Texas
$4 – – –
VC
130
Vivo Capital
California
– -$10.5M -856,008 Closed
CM
131
Caption Management
Oklahoma
– -$2.02M -165,000 Closed
OM
132
Opaleye Management
Massachusetts
– -$1.84M -150,000 Closed
AAA
133
Affinity Asset Advisors
New York
– -$1.54M -125,969 Closed
CSS
134
Cubist Systematic Strategies
Connecticut
– -$181K -14,772 Closed
Balyasny Asset Management
135
Balyasny Asset Management
Illinois
– -$146K -11,905 Closed
BCM
136
Bridgeway Capital Management
Texas
– -$129K -10,500 Closed
A
137
AJOVista
Massachusetts
– -$60.3K -4,920 Closed
Belvedere Trading
138
Belvedere Trading
Illinois
– -$51.1K -4,170 Closed
GAMC
139
Garner Asset Management Corp
Texas
– -$1.96K -135 Closed
PNC Financial Services Group
140
PNC Financial Services Group
Pennsylvania
– -$61 -5 Closed
2 3 4 5
6

KALV Hedge Fund Activity: Q1 2024 in Review

128 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in KalVista Pharmaceuticals (KALV) for Q1 2024, worth a combined $557M — up 22% from $459M a quarter earlier.

Buyers outnumbered sellers: 46 funds opened new KALV positions and 11 closed out — a net gain of 35 holders — while 33 added to existing stakes and 35 trimmed.

The largest buyer was VR Adviser, adding an estimated $28.8M. The largest seller was TCG Crossover Management, cutting an estimated $29.8M.

  • 128 institutional investors held KalVista Pharmaceuticals (KALV) as of Q1 2024, up from 93 in Q4 2023.
  • Funds reported $557M of KalVista Pharmaceuticals stock for Q1 2024, up 22% quarter-over-quarter.
  • 46 funds opened new KalVista Pharmaceuticals positions in Q1 2024 and 11 closed out, a net change of +35 holders.
  • The largest KalVista Pharmaceuticals buyer in Q1 2024 was VR Adviser, an estimated $28.8M added.
  • The largest KalVista Pharmaceuticals seller in Q1 2024 was TCG Crossover Management, an estimated $29.8M sold.

Based on aggregated 13F filings for Q1 2024.